Cargando…

Optimization of New Catalytic Topoisomerase II Inhibitors as an Anti-Cancer Therapy

SIMPLE SUMMARY: DNA topoisomerase II (TOP2) is a drug target for many types of cancers. However, clinically used TOP2 inhibitors not only kill cancer cells, but also damage normal cells, and can even give rise to other types of cancers. To discover new TOP2 inhibitors to more effectively treat cance...

Descripción completa

Detalles Bibliográficos
Autores principales:	Matias-Barrios, Victor M., Radaeva, Mariia, Ho, Chia-Hao, Lee, Joseph, Adomat, Hans, Lallous, Nada, Cherkasov, Artem, Dong, Xuesen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8345109/ https://www.ncbi.nlm.nih.gov/pubmed/34359577 http://dx.doi.org/10.3390/cancers13153675

Ejemplares similares

Discovery of New Catalytic Topoisomerase II Inhibitors for Anticancer Therapeutics
por: Matias-Barrios, Victor M., et al.
Publicado: (2021)

Discovery of Novel Lin28 Inhibitors to Suppress Cancer Cell Stemness
por: Radaeva, Mariia, et al.
Publicado: (2022)

PurificationDB: database of purification conditions for proteins
por: Garland, Olivia, et al.
Publicado: (2023)

The Implication of Topoisomerase II Inhibitors in Synthetic Lethality for Cancer Therapy
por: Matias-Barrios, Victor M., et al.
Publicado: (2023)

Development of Novel Inhibitors Targeting the D-Box of the DNA Binding Domain of Androgen Receptor
por: Radaeva, Mariia, et al.
Publicado: (2021)

Lin28 Regulates Cancer Cell Stemness for Tumour Progression
por: Lin, Zhuohui, et al.
Publicado: (2022)

Structure-Based Study to Overcome Cross-Reactivity of Novel Androgen Receptor Inhibitors
por: Radaeva, Mariia, et al.
Publicado: (2022)

Catalytic inhibitors of DNA topoisomerase II suppress the androgen receptor signaling and prostate cancer progression
por: Li, Haolong, et al.
Publicado: (2015)

Targeting Alternative Sites on the Androgen Receptor to Treat Castration-Resistant Prostate Cancer
por: Lallous, Nada, et al.
Publicado: (2013)

Deep Learning Modeling of Androgen Receptor Responses to Prostate Cancer Therapies
por: Snow, Oliver, et al.
Publicado: (2020)

Phase I and pharmacokinetic study of the topoisomerase II catalytic inhibitor fostriecin
por: Jong, R S de, et al.
Publicado: (1999)

Dual-Inhibitors of N-Myc and AURKA as Potential Therapy for Neuroendocrine Prostate Cancer
por: Ton, Anh-Tien, et al.
Publicado: (2020)

Ligand Binding Prediction Using Protein Structure Graphs and Residual Graph Attention Networks
por: Pandey, Mohit, et al.
Publicado: (2022)

Catalytic Inhibitors of Topoisomerase II Differently Modulate the Toxicity of Anthracyclines in Cardiac and Cancer Cells
por: Vavrova, Anna, et al.
Publicado: (2013)

Substituted 4,5′-Bithiazoles as Catalytic Inhibitors of Human DNA Topoisomerase IIα
por: Bergant Loboda, Kaja, et al.
Publicado: (2020)

Design, Synthesis and Anti-Tumor Activity of Novel Benzimidazole-Chalcone Hybrids as Non-Intercalative Topoisomerase II Catalytic Inhibitors
por: Zhou, Wei, et al.
Publicado: (2020)

In silico discovery and validation of potent small-molecule inhibitors targeting the activation function 2 site of human oestrogen receptor α
por: Singh, Kriti, et al.
Publicado: (2015)

Development of VPC-70619, a Small-Molecule N-Myc Inhibitor as a Potential Therapy for Neuroendocrine Prostate Cancer
por: Ton, Anh-Tien, et al.
Publicado: (2022)

Hyperthermia, thermotolerance and topoisomerase II inhibitors.
por: Kampinga, H. H.
Publicado: (1995)

Regulation of the catalytic function of topoisomerase II alpha through association with RNA
por: Park, Seung-Won, et al.
Publicado: (2008)

Non-Catalytic Roles of the Topoisomerase IIα C-Terminal Domain
por: Clarke, Duncan J., et al.
Publicado: (2017)

Computer-Aided Discovery of Small Molecules Targeting the RNA Splicing Activity of hnRNP A1 in Castration-Resistant Prostate Cancer
por: Carabet, Lavinia A., et al.
Publicado: (2019)

MSN8C: A Promising Candidate for Antitumor Applications as a Novel Catalytic Inhibitor of Topoisomerase II
por: Ou, Jie-Bin, et al.
Publicado: (2023)

Cell Cycle–coupled Relocation of Types I and II Topoisomerases and Modulation of Catalytic Enzyme Activities
por: Meyer, Kay N., et al.
Publicado: (1997)

Mechanisms regulating resistance to inhibitors of topoisomerase II
por: Ganapathi, Ram N., et al.
Publicado: (2013)

AK-I-190, a New Catalytic Inhibitor of Topoisomerase II with Anti-Proliferative and Pro-Apoptotic Activity on Androgen-Negative Prostate Cancer Cells
por: Jeon, Kyung-Hwa, et al.
Publicado: (2021)

Casein kinase II–dependent phosphorylation of DNA topoisomerase II suppresses the effect of a catalytic topo II inhibitor, ICRF-193, in fission yeast
por: Nakazawa, Norihiko, et al.
Publicado: (2019)

Secondary Leukemia Associated with the Anti-Cancer Agent, Etoposide, a Topoisomerase II Inhibitor
por: Ezoe, Sachiko
Publicado: (2012)

Benzothiophenone Derivatives Targeting Mutant Forms of Estrogen Receptor-α in Hormone-Resistant Breast Cancers
por: Singh, Kriti, et al.
Publicado: (2018)

HMGB1 interacts with human topoisomerase IIα and stimulates its catalytic activity
por: Štros, Michal, et al.
Publicado: (2007)

Catalytic Mechanism of ATP Hydrolysis in the ATPase Domain of Human DNA Topoisomerase IIα
por: Ogrizek, Mitja, et al.
Publicado: (2022)

Relationship between expression of topoisomerase II isoforms and intrinsic sensitivity to topoisomerase II inhibitors in breast cancer cell lines.
por: Houlbrook, S., et al.
Publicado: (1995)

Relationship between expression of topoisomerase II isoforms and intrinsic sensitivity to topoisomerase II inhibitors in breast cancer cell lines
Publicado: (1996)

Preclinical antitumour activity of F 11782, a novel dual catalytic inhibitor of topoisomerases
por: Kruczynski, A, et al.
Publicado: (2000)

Gold(III) Macrocycles: Nucleotide-Specific Unconventional Catalytic Inhibitors of Human Topoisomerase I
por: Akerman, Kate J., et al.
Publicado: (2014)

The antitumor activity of CYB-L10, a human topoisomerase IB catalytic inhibitor
por: Yu, Qian, et al.
Publicado: (2019)

Prospects of Topoisomerase Inhibitors as Promising Anti-Cancer Agents
por: Yakkala, Prasanna Anjaneyulu, et al.
Publicado: (2023)

Catalytic inhibition of topoisomerase II by a novel rationally designed ATP-competitive purine analogue
por: Chène, Patrick, et al.
Publicado: (2009)

Catalytic Core of Human Topoisomerase IIα: Insights into Enzyme–DNA Interactions and Drug Mechanism
por: Lindsey, R. Hunter, et al.
Publicado: (2014)

Exploration of the Role of the C-Terminal Domain of Human DNA Topoisomerase IIα in Catalytic Activity
por: Dougherty, Ashley C., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_dmamajsvd76b0vfli3gi3gtsk5